Efficacy and safety of warming Yang and dredging intestines method in metastatic colon cancer maintenance.

IF 3.2 Q3 ONCOLOGY
Yu-Xing Sun, Tong Zhang, Jiang-Yu Bian, Wen-Ting He, Xue-Qian Wang, Chuan-Bo Liu
{"title":"Efficacy and safety of warming Yang and dredging intestines method in metastatic colon cancer maintenance.","authors":"Yu-Xing Sun, Tong Zhang, Jiang-Yu Bian, Wen-Ting He, Xue-Qian Wang, Chuan-Bo Liu","doi":"10.5306/wjco.v16.i6.105175","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a lack of integrated Chinese and Western medicine treatment regimens supported by high-level evidence-based medicine in the maintenance therapy phase of metastatic colorectal cancer (mCRC). Based on the traditional Chinese medicine theory of \"Yin tumor\", we believe that \"Yang does not transform Yin, and it is blocked in the intestines\" is the core pathogenesis of mCRC. Based on the basic treatment principle of \"warming Yang and dredging intestines\", we developed the Quxie Capsule. Previous randomized controlled clinical trials demonstrated that the Quxie Capsule can significantly prolong the overall survival of patients with mCRC, but it remains to be verified whether the combination of the \"warming Yang and dredging intestines method\" prescription with Western medicine standard regimen can prolong the efficacy and safety of the mCRC during the period of maintenance therapy.</p><p><strong>Aim: </strong>To confirm and clinically validate that the combination of \"warming Yang and dredging intestines method\" prescription with Western medicine standard regimen can prolong progression-free survival (PFS) during maintenance treatment of mCRC. The safety of \"warming Yang and dredging intestines method\" prescription is also assessed.</p><p><strong>Methods: </strong>The study has a prospective, open-label, randomized, controlled study design. Patients have been recruited beginning November 2023 from Xiyuan Hospital of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Dongfang Hospital of Beijing University of Chinese Medicine, and Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine. The study period is from March 2024 to March 2026. After screening in outpatient clinics or wards, subjects who met the inclusion criteria are randomized into the treatment or control group in a 2:1 ratio. The treatment group receives the \"warming Yang and dredging intestines method\" formula combined with Western standard maintenance therapy. The control group receives Western standard maintenance therapy formulated by the investigators based on the Chinese Society of Clinical Oncology guidelines for colorectal cancer. All participants receive treatment until the occurrence of disease progression, death, or unmanageable adverse effects, with post-treatment monitoring continued until mortality. An independent panel of chief physicians with extensive clinical experience evaluates the progression of the disease.</p><p><strong>Results: </strong>This study aims to clarify whether the combination of warming Yang and dredging intestines method formula with standard Western medicine regimens can prolong PFS during maintenance therapy for mCRC and whether the treatment has a favorable safety profile. The goal is to provide a combined Chinese and Western medicine treatment option for clinical physicians and mCRC patients. Notably, with the actual sample size, this study has an 80% probability of detecting a significant difference if a true difference exists. Small sample sizes may lead to increased instability of the results of subgroup analyses, and may also result in findings that are only applicable to patients with characteristics highly similar to those of the present study population (<i>e.g.</i>, specific genotypes, therapeutic backgrounds, <i>etc.</i>), making it difficult to generalize to the broader mCRC population. In the future, it may be possible to expand the sample size based on this study to further validate the efficacy and safety of combining Chinese and Western medicine in the treatment of mCRC. Basic research on the therapeutic combination of warming Yang and dredging intestines method formula and standard Western regimen will be performed in parallel.</p><p><strong>Conclusion: </strong>This study aims to clarify whether the combination of warming Yang and dredging intestines method formula with standard Western medicine regimens can prolong PFS during maintenance therapy for mCRC and whether the treatment has a favorable safety profile.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105175"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203225/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i6.105175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is a lack of integrated Chinese and Western medicine treatment regimens supported by high-level evidence-based medicine in the maintenance therapy phase of metastatic colorectal cancer (mCRC). Based on the traditional Chinese medicine theory of "Yin tumor", we believe that "Yang does not transform Yin, and it is blocked in the intestines" is the core pathogenesis of mCRC. Based on the basic treatment principle of "warming Yang and dredging intestines", we developed the Quxie Capsule. Previous randomized controlled clinical trials demonstrated that the Quxie Capsule can significantly prolong the overall survival of patients with mCRC, but it remains to be verified whether the combination of the "warming Yang and dredging intestines method" prescription with Western medicine standard regimen can prolong the efficacy and safety of the mCRC during the period of maintenance therapy.

Aim: To confirm and clinically validate that the combination of "warming Yang and dredging intestines method" prescription with Western medicine standard regimen can prolong progression-free survival (PFS) during maintenance treatment of mCRC. The safety of "warming Yang and dredging intestines method" prescription is also assessed.

Methods: The study has a prospective, open-label, randomized, controlled study design. Patients have been recruited beginning November 2023 from Xiyuan Hospital of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Dongfang Hospital of Beijing University of Chinese Medicine, and Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine. The study period is from March 2024 to March 2026. After screening in outpatient clinics or wards, subjects who met the inclusion criteria are randomized into the treatment or control group in a 2:1 ratio. The treatment group receives the "warming Yang and dredging intestines method" formula combined with Western standard maintenance therapy. The control group receives Western standard maintenance therapy formulated by the investigators based on the Chinese Society of Clinical Oncology guidelines for colorectal cancer. All participants receive treatment until the occurrence of disease progression, death, or unmanageable adverse effects, with post-treatment monitoring continued until mortality. An independent panel of chief physicians with extensive clinical experience evaluates the progression of the disease.

Results: This study aims to clarify whether the combination of warming Yang and dredging intestines method formula with standard Western medicine regimens can prolong PFS during maintenance therapy for mCRC and whether the treatment has a favorable safety profile. The goal is to provide a combined Chinese and Western medicine treatment option for clinical physicians and mCRC patients. Notably, with the actual sample size, this study has an 80% probability of detecting a significant difference if a true difference exists. Small sample sizes may lead to increased instability of the results of subgroup analyses, and may also result in findings that are only applicable to patients with characteristics highly similar to those of the present study population (e.g., specific genotypes, therapeutic backgrounds, etc.), making it difficult to generalize to the broader mCRC population. In the future, it may be possible to expand the sample size based on this study to further validate the efficacy and safety of combining Chinese and Western medicine in the treatment of mCRC. Basic research on the therapeutic combination of warming Yang and dredging intestines method formula and standard Western regimen will be performed in parallel.

Conclusion: This study aims to clarify whether the combination of warming Yang and dredging intestines method formula with standard Western medicine regimens can prolong PFS during maintenance therapy for mCRC and whether the treatment has a favorable safety profile.

温阳疏肠法维持转移性结肠癌的疗效及安全性。
背景:转移性结直肠癌(mCRC)维持治疗阶段缺乏高水平循证医学支持的中西医结合治疗方案。基于中医“阴肿瘤”理论,我们认为“阳不化阴,阻于肠”是mCRC的核心病机。根据“温阳通肠”的基本治疗原理,研制出祛邪胶囊。既往的随机对照临床试验表明祛泻胶囊能显著延长mCRC患者的总生存期,但“温阳疏肠法”方剂与西药标准方案相结合是否能延长mCRC维持治疗期间的疗效和安全性还有待验证。目的:确认并临床验证“温阳通肠法”方剂配合西药标准方案可延长mCRC维持治疗期间的无进展生存期(PFS)。并对温阳疏肠方剂的安全性进行了评价。方法:本研究采用前瞻性、开放标签、随机对照研究设计。患者从2023年11月开始从中国中医科学院西苑医院、中国中医科学院广安门医院、北京中医药大学东方医院和新疆维吾尔自治区中医医院招募。研究时间为2024年3月至2026年3月。在门诊或病房筛选后,符合纳入标准的受试者按2:1的比例随机分为治疗组和对照组。治疗组采用“温阳疏肠法”方剂结合西方标准维持疗法。对照组接受研究者根据中国临床肿瘤学会结直肠癌指南制定的西式标准维持治疗。所有参与者接受治疗,直到出现疾病进展、死亡或无法控制的不良反应,治疗后监测持续到死亡。由具有丰富临床经验的主任医师组成的独立小组评估疾病的进展。结果:本研究旨在阐明温阳通肠法方剂与标准西药方案相结合是否可以延长mCRC维持治疗期间的PFS,以及该治疗是否具有良好的安全性。目的是为临床医生和mCRC患者提供一种中西医结合的治疗选择。值得注意的是,根据实际样本量,如果存在真正的差异,本研究有80%的概率检测到显著差异。小样本量可能导致亚组分析结果的不稳定性增加,也可能导致研究结果仅适用于与本研究人群特征高度相似的患者(例如,特定基因型、治疗背景等),因此难以推广到更广泛的mCRC人群。未来可能在本研究的基础上扩大样本量,进一步验证中西医结合治疗mCRC的疗效和安全性。温阳通肠法方剂与西医标准疗法结合治疗的基础研究将并行进行。结论:本研究旨在阐明温阳通肠法方剂配合标准西药方案是否能延长mCRC维持治疗期间的PFS,以及该疗法是否具有良好的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
585
期刊介绍: The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信